Know Cancer

forgot password

Study of GSK2241658A Antigen-Specific Cancer Immunotherapeutic in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma

Phase 1
18 Years
Open (Enrolling)
NY-ESO-1-positive, Unresectable and Progressive Metastatic Cutaneous Melanoma

Thank you

Trial Information

Study of GSK2241658A Antigen-Specific Cancer Immunotherapeutic in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma

Inclusion Criteria:

- Male or female patient with histologically proven, measurable metastatic cutaneous
melanoma, and with documented progressive disease within the 12 weeks before the
first administration of study treatment.

- Written informed consent for NY-ESO-1 expression screening and gene profiling on
resected tumor tissue and for the complete study has been obtained from the patient
prior to shipment of the sample for expression testing and prior to the performance
of any other protocol-specific procedure.

- Patient is >= 18 years of age at the time of signature of the informed consent.

- The patient's tumor shows expression of NY-ESO-1, as determined by real-time
quantitative reverse transcription polymerase chain reaction (RT-PCR) analysis or any
updated technique on fresh tissue sample(s).

- Eastern Cooperative Oncology Group performance status of 0 or 1.

- The patient has normal organ functions as shown by all of the following:

- Hemoglobin ≥ 12 g/dL

- Absolute leukocytes count ≥ 3.0 x 1000000000/L

- Absolute lymphocytes count ≥ 1.0 x 1000000000/L

- Platelets ≥ 100 x 1000000000/L

- Serum creatinine ≤ Upper Limit of Normal (ULN)

- Serum total bilirubin ≤ 1.5 x ULN (except for patients with Gilbert's syndrome
for whom the limit is 2 x ULN)

- Lactate dehydrogenase ≤ ULN

- Aspartate aminotransferase ≤ 2 × ULN

- Alanine aminotransferase ≤ 2 × ULN

These tests must be done no more than 3 weeks before the first ASCI administration.

- Female patients of non-childbearing potential may be enrolled in the study.

- Female patient of childbearing potential may be enrolled in the study, if the

- has practiced adequate contraception for 30 days prior to first ASCI
administration, and

- has a negative pregnancy test at the specified study visits, and

- has agreed to continue adequate contraception during the entire treatment period
and for 2 months after completion of the ASCI administration series.

- In the view of the investigator, the patient can and will comply with the
requirements of this protocol.

Exclusion Criteria:

- The patient has at any time received systemic chemotherapy, biochemotherapy, small
molecules or nti-CTLA-4 monoclonal antibody for metastatic disease.

- The patient is scheduled to receive any other anticancer treatments than those
specified in the protocol, including but not limited to (bio-) chemotherapeutic,
immunomodulating agents and radiotherapy.

- The patient received any cancer immunotherapy containing a NY-ESO-1 antigen or any
cancer immunotherapy for his/her metastatic disease.

- The patient requires concomitant treatment with systemic corticosteroids, or any
other immunosuppressive agents.

- Use of any investigational or non-registered product other than the ASCI within 30
days preceding the first ASCI administration, or planned use during the study period.

- The patient has (had) previous or concomitant malignancies at other sites, except
effectively treated non-melanoma skin cancers or carcinoma in situ of the cervix or
effectively treated malignancy that has been in remission for over 5 years and is
highly likely to have been cured.

- The patient has an allergy to any component of the study investigational product or
has a history of previous allergic reactions to vaccinations.

- The patient has an autoimmune disease such as, but not limited to, multiple
sclerosis, lupus, and inflammatory bowel disease. Patients with vitiligo are not

- The patient has a family history of congenital or hereditary immunodeficiency.

- The patient is known to be positive for the Human Immunodeficiency Virus.

- The patient has an uncontrolled bleeding disorder.

- The patient has a family history of congenital or hereditary immunodeficiency.

- The patient has psychiatric or addictive disorders that may compromise his/her
ability to give informed consent, or to comply with the trial procedures.

- The patient has concurrent severe medical problems, unrelated to the malignancy, that
would significantly limit full compliance with the study or expose the patient to
unacceptable risk.

- For female patients: the patient is pregnant or lactating.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Occurrence of severe toxicities.

Outcome Time Frame:

On continuous basis during the study treatment period (49 months) and active follow-up period (one year).

Safety Issue:


Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:



Netherlands: Minister van VWS Medische Technologie

Study ID:




Start Date:

January 2011

Completion Date:

December 2018

Related Keywords:

  • NY-ESO-1-positive, Unresectable and Progressive Metastatic Cutaneous Melanoma
  • ASCI
  • melanoma
  • tumor antigen
  • unresectable
  • progressive
  • NY-ESO-1
  • adult
  • cancer-testis antigen
  • Immunotherapy
  • Melanoma
  • Skin Neoplasms



GSK Investigational Site Gainesville, Florida  32610
GSK Investigational Site Fort Worth, Texas  76104
GSK Investigational Site Royal Oak, Michigan  48073